Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Identifies New Mineralised Trends and Refines Targeting with Magnetic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bone Biologics Corp BBLG

Healthcare Biotechnology
Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant... see more

Recent & Breaking News (NDAQ:BBLG)

Bone Biologics Announces 1-for-6 Reverse Stock Split

Business Wire 7 days ago

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Business Wire October 21, 2024

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire September 4, 2024

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Business Wire August 2, 2024

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

Business Wire June 20, 2024

Bone Biologics Announces Closing of $2.0 Million Public Offering

Business Wire March 6, 2024

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Business Wire March 4, 2024

Bone Biologics Reports Progress With NB1 Clinical Program

Business Wire March 1, 2024

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

Business Wire January 11, 2024

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Business Wire January 10, 2024

Bone Biologics Announces 1-for-8 Reverse Stock Split

Business Wire December 18, 2023

Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Business Wire November 20, 2023

Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Business Wire November 16, 2023

Bone Biologics Provides Scientific Update on NB1 Bone Graft Device

Business Wire September 26, 2023

Bone Biologics Prices $5.0 Million Underwritten Public Offering

Business Wire June 14, 2023

Bone Biologics Effects 1-for-30 Reverse Stock Split

Business Wire June 6, 2023

Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

Business Wire April 11, 2023

Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

Business Wire January 26, 2023

Bone Biologics CEO Issues Letter to Stockholders

Business Wire October 25, 2022

WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering

PR Newswire October 13, 2022